Phoenix Pharmaceuticals, Inc.
Burlingame, CA
- UEI
- P8XLC937AAK3
- CAGE
- 3F7E4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 330 Beach Rd, Burlingame, CA 94010, USA
- Website
- phoenixpeptide.com
- Founded
- 1994
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Phoenix Pharmaceuticals, Inc., doing business as Phoenix Pharmaceuticals, is a minority-owned, Asian-Pacific American-owned manufacturer of goods registered to receive federal government awards since June 23, 2003. The company specializes in providing biological materials, blood products, and other pharmaceutical-related goods to various federal agencies, particularly within the Department of Health and Human Services. As a for-profit organization, Phoenix Pharmaceuticals has established itself as a reliable supplier of specialized pharmaceutical and biological products for government research and medical applications.
The company's recent federal contract awards demonstrate its expertise in providing specialized peptide and protein products for scientific research. In September 2021, Phoenix Pharmaceuticals received a purchase order from the National Institute on Drug Abuse for an unspecified product or service, with a ceiling value of $11,695.78. Previously, in August 2020, the company was awarded a contract by the National Center for Advancing Translational Sciences for a G-protein coupled receptor (GPCR) peptide ligand library, valued at $23,784.21. These awards highlight Phoenix Pharmaceuticals' capability to supply highly specific biological materials crucial for advanced scientific research in drug development and translational medicine. Both contracts were awarded without set-asides, indicating the company's competitiveness in open bidding processes.
Phoenix Pharmaceuticals currently holds a significant federal contract Indefinite Delivery Vehicle (IDV) in the form of a Blanket Purchase Agreement (BPA) awarded by the Department of Health and Human Services' National Institutes of Health Office of Logistics and Acquisition Operations. This single-award BPA, established on May 30, 2024, has a substantial ceiling value of $100,000,000 and extends through May 31, 2025. The agreement covers the provision of biological materials and blood/blood products, positioning Phoenix Pharmaceuticals as a key supplier of these critical resources to the NIH. This large-scale, non-set-aside BPA underscores the company's capacity to meet substantial federal demand for specialized biological and pharmaceutical products, further cementing its role as a trusted partner in supporting government research and medical initiatives.
Quick answers
Is Phoenix Pharmaceuticals, Inc. registered in SAM.gov?
Yes. Phoenix Pharmaceuticals, Inc.'s SAM.gov registration is active through March 3, 2027.
What is Phoenix Pharmaceuticals, Inc.'s most recent federal award?
Phoenix Pharmaceuticals, Inc.'s most recent federal contract award is Phoenix pharmaceuticals INC:1109673 [21-005342] (75N95021P00546), from National Institute on Drug Abuse (NIH), on September 9, 2021.
On GovTribe
See Phoenix Pharmaceuticals, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors